Adverse Event Management: What’s the Limiting Factor?
We want to hear from you: what is the limiting factor in managing adverse events in patients with cancer?
The American Society of Pharmacovigilance officially announced that today, March 24, is National Adverse Drug Event Awareness Day. In the oncology world, nurses are leaders in adverse event (AE) management.
While nurses are skilled in helping patients through a variety of symptoms – from nausea to neuropathy – communication barriers may exist between patients and providers, leading to unchecked toxicities that diminish patient health and quality-of-life. For example, research shows that patients receiving immunotherapy may not report AEs, in fear of being taken off treatment. In this situation, reassurance from the nurse is critical.1
Patients may also be unaware of what kind of AEs are important to look out for and report to their care team, or may not have a solid understanding of their cancer treatment plan.This points toward the importance of patient education.2
We want to hear from you on the biggest barriers to AE management in patients with cancer.
What is the biggest/most frequent barrier when it comes to adverse event management?
Read more on adverse event management.
References
- Fecher LA, et. al. Ipilimumab and its toxicities: a multidisciplinary approach. The Oncologist. June 17, 2013. https://doi.org/10.1634/theoncologist.2012-0483. Accessed March 24, 2021.
- Wood LS, Moldwer NP, Lewis C. Immune checkpoint inhibitor therapy: key principles when educating patients. Clinical Journal of Oncology Nursing. CJON 2019, 23(3), 271-280 DOI: 10.1188/19.CJON.271-280. Accessed March 24, 2021.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
Increasing Awareness of Audiovestibular Adverse Events From Immune Checkpoint Inhibitors
July 16th 2024Oncology nurses play a critical role in identifying and managing rare audiovestibular complications associated with immune checkpoint inhibitors to prevent permanent hearing loss and improve patients' quality of life.
